Huang Dayu, Zhao Deping, Zhou Yiming, Liu Hongchen, Chen Xiaofeng
Department of Cardiothoracic Surgery, Huashan Hospital of Fudan University, Shanghai, 200040, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University, Shanghai, 200433, China.
World J Surg. 2016 May;40(5):1121-8. doi: 10.1007/s00268-015-3378-9.
Many studies have described the use of intrapleural fibrinolytics for the treatment of complex pleural processes and traumatic hemothorax, but data are scarce regarding their use for hemothorax after lung surgery.
To evaluate the utility of intrapleural fibrinolytic therapy with urokinase for residual coagulated hemothorax (blood clot accumulation in the pleural cavity) after lung surgery.
From July 2009 to November 2013, 46 patients (33 males; mean age, 56.9 ± 10.7 years) were treated with intrapleural urokinase (250,000 IU per dose) for residual hemothorax after lung surgery. Complete response was defined as clinical improvement with complete drainage of the retained collection shown by chest X-ray, and partial response as substantial resolution with minimal residual opacity (<25 % of the thorax). Follow-up was at least 30 days.
The procedure was successful in 42 patients (91.3 %), with complete response observed in 35/46 patients (76.1 %) and partial response in 7/46 (15.2 %). These 42 patients did not require re-intervention for fluid accumulation in the pleural cavity. Treatment failed in 4 patients (8.7 %): one developed bronchopleural fistula that later resolved spontaneously and three (6.5 %) required thoracoscopic drainage for pleural cavity fluid accumulation and lung collapse. No patient required thoracotomy for total decortication. Intrapleural urokinase administration was not associated with serious adverse events, including bleeding complications or allergic reactions.
Intrapleural fibrinolytic agents should be considered a useful therapeutic option for the treatment of postoperative residual hemothorax. This method appears to be safe and effective in >90 % of patients with postoperative hemothorax.
许多研究描述了胸膜内纤维蛋白溶解剂用于治疗复杂的胸膜疾病和创伤性血胸,但关于其在肺手术后血胸治疗中的应用数据较少。
评估尿激酶胸膜内纤维蛋白溶解疗法对肺手术后残留凝固性血胸(胸腔内血凝块积聚)的效用。
2009年7月至2013年11月,46例患者(33例男性;平均年龄56.9±10.7岁)接受胸膜内尿激酶(每剂250,000国际单位)治疗肺手术后残留血胸。完全缓解定义为临床改善且胸部X线显示留存积液完全引流,部分缓解定义为大部分消退且残留不透明度最小(<胸腔的25%)。随访至少30天。
该治疗方法在42例患者(91.3%)中成功,46例患者中有35例(76.1%)观察到完全缓解,7例(15.2%)为部分缓解。这42例患者无需因胸腔积液再次干预。治疗失败4例(8.7%):1例发生支气管胸膜瘘,随后自发缓解,3例(6.5%)因胸腔积液和肺萎陷需要胸腔镜引流。无患者需要开胸进行全胸膜剥脱术。胸膜内给予尿激酶与严重不良事件无关,包括出血并发症或过敏反应。
胸膜内纤维蛋白溶解剂应被视为治疗术后残留血胸的有用治疗选择。该方法在>90%的术后血胸患者中似乎安全有效。